Compare IMPP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMPP | MGNX |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.7M | 262.4M |
| IPO Year | 2021 | 2013 |
| Metric | IMPP | MGNX |
|---|---|---|
| Price | $4.98 | $3.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 438.3K | ★ 544.4K |
| Earning Date | 09-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | $86.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.15 | $1.29 |
| 52 Week High | $6.57 | $5.08 |
| Indicator | IMPP | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 36.53 |
| Support Level | $4.83 | $2.78 |
| Resistance Level | $5.00 | $3.39 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 24.39 | 13.33 |
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.